

# Anthrax Bioterrorism, 2001 Lessons from the Front Lines



David A. Ashford, DVM, MPH, DSc  
Attache  
Liaison - PANAFTOSA  
USDA – APHIS  
International Services

# Outline

- **Investigation – Florida and Washington, D.C**
  - **What were lessons at each step?**
- **What were the challenges faced that might guide preparedness activities for any outbreak response?**

# Outline

- **Investigation – Florida and Washington, D.C**
  - **What were lessons at each step?**
- **What were the challenges faced that might guide preparedness and research activities in anticipation of the next attack?**

# Objectives of Epidemiological Investigation

## 1) Determine the pathogen

- Create the differential based on symptoms – history
- Environmental testing may lead to early detection
- Confirm Agent – Identify

## 2) Determine the source of the pathogen

- Natural?
- Nefarious?

## 3) Reduce any further health threat from exposure – eliminate the source

## 4) Define the exposed populations for control

## 5) Remediate and test the effectiveness of remediation – clearance

# Recognition: Palm Beach County, Florida




- **CDC notification 10/3**
- **63 yo male photo editor employed by American Media, Inc.**
- **Onset 9/30/01: fever, fatigue, sweats, altered mental status**
- **Admitted to hospital 10/2**
- **History of traveling to New Hampshire in incubation period by car – 1200 miles**

# Objectives of Epidemiological Investigation

- 1) Determine the pathogen
  - Create the differential based on symptoms – history
  - Environmental testing may lead to early detection
- 2) Determine the source of the pathogen
  - Natural?
  - Nefarious? – de mal intencao
- 3) Reduce any further health threat from exposure – eliminate the source
- 4) Define the exposed populations for control
- 5) Remediate and evaluate the effectiveness of remediation clearance

# Cerebrospinal Fluid Stain

## Florida Index Case



### Lessons:

- Let's not forget stains and microscopy (restrictions?)
- Clinical labs are the front-line first responders with their health care providers
- Are they ready for threat agents?

# Objectives of Epidemiological Investigation

## 1) Determine the pathogen

- Create the differential based on symptoms – history
- Environmental testing may lead to early detection
- **Identify the Agent - Confirm**

## 2) Determine the source of the pathogen

- Natural?
- Nefarious?

## 3) Reduce any further health threat from exposure – eliminate the source



# Confirmation of the Agent

- Night of October 3 low altitude plane transports laboratory culture sample from Florida State Laboratory to CDC
- Arrives at 23:00 in Atlanta, Georgia
- Confirmation in multiple testing as *B. anthracis* by 03:00 am

# Objectives of Epidemiological Investigation

## 1) Determine the pathogen

- Create the differential based on symptoms – history
- Environmental testing may lead to early detection
- Identify the Agent - Confirm

## 2) Determine the source of the pathogen

- Natural?
- Nefarious?

## 3) Reduce any further health threat from exposure – eliminate the source

# Friday, October 5, 2001: The Home



## Lessons:

- Entry guidelines, sampling guidelines were not ready
- What constitutes a good environmental investigation?

# Friday, October 5, 2001: The Workplace



# Friday, October 5: Index Case Work Space



## Lessons:

- Surface sampling protocols and validation needed
- Risk to those sampling?

# Friday, October 5: Define Exposure Area

Workplace Mailroom



# Nefarious or Natural

- Work place cultures positive in 24 hours
- = NEFARIOUS

# Friday, October 5, The Workplace

FBI



Public Health




## Lessons

- New partnerships worked well together
- Practice will be essential
- Adequate hazardous operations training?



# Friday, October 5: Hospitalized “Pneumonia” in Co-worker




- 73 y/o mailroom supervisor hospitalized Oct 1
- No mediastinal lymphadenopathy
- Hemorrhagic re-accumulating pleural effusions

## Lesson

- Variable clinical findings
  - Epidemiology confirms
- Nefarious**

# Patient Expired Oct 5

## Autopsy Consistent with Inhalational Anthrax



### Lessons

- IHC developed in anticipation of event
- Critical

# Objectives of Epidemiological Investigation

## 1) Determine the pathogen

- Create the differential based on symptoms – history
- Environmental testing may lead to early detection

## 2) Determine the source of the pathogen

- Natural?
- Nefarious?

## 3) Reduce any further health threat from exposure – eliminate the source

## 4) Define the exposed populations for control

# Monday, October 8: Assessing Exposed and Providing Intervention



## Lessons

- Samples collected from those in building
- Antibiotic prophylaxis offered to workplace employees & visitors (n=1,114)
  - Why – considered single air space
- Nasal swabs: 1 of 1,075 positive
- Serosurvey: 0 of 436 positive
- Exposure assessment with clinical lab tests difficult at best
  - Potentially, nasal swabs not useful for long
  - Serology apparently not useful, but exposed?
- Rapid distribution plans for antibiotics are needed
- Stockpile and delivery were ready and successful

# Recognition: New York City



- Suspect cutaneous case reported 10/11
- Female, 38 y/o, NBC TV anchor assistant
- Onset 9/25
- Immunohistochemical staining of skin biopsy showed *B. anthracis* on 10/12
- Recalled handling letter with powder
- Postmarked from Trenton, NJ, Sept 18
- Powder subsequently positive for *B. anthracis*

## Lessons

- Cutaneous anthrax is a risk following BT release
- Antibiotic treatment complicates diagnosis
  - “Typical” presentation may be changed
  - Laboratory confirmation is difficult

# Epidemiologic Investigations



# Recognition: Senator Daschle Suite, Capitol Hill, Monday, October 15 @ 9:45 A.M.




## Lessons


- BT training of staff paid off

# Define Exposure Area and Population at Risk

## Contiguous Separate Air Space




Southeast quadrant Hart  
Senate Office Building: 5<sup>th</sup>  
and 6<sup>th</sup> floors





# Define Exposure – Nasal Swabs

Hart Senate  
Office Building  
SE Quadrant  
6<sup>th</sup> Floor



- Daschle/Feingold offices
- Internal staircase
- Person opening envelope
- A person with a positive nasal swab

# 6<sup>th</sup> Floor Persons with Positive Nasal Swabs

Location	Total No.	Positive NS No.	(%)
<b>Daschle office</b>			
Staff	13	13	(100)
Responders	5	5	(100)
<b>Feingold office</b>			
Staff	15	2	(13)
<b>Hallway</b>			
Responders	unk.	1	unk.

# Defining Population at Risk: Hart SE Quadrant, 5<sup>th</sup> and 6<sup>th</sup> Floors

Category		Total No.	Positive NS*
			No.
Senate Staff	Daschle	38	20
	Feingold	27	2
	Other	252	0
Known visitors		66	0
Responders		59	6
<b>Total</b>		<b>442</b>	<b>28</b>

\*NS= Nasal Swab

## Lessons

- Responders exposed (risk of disease?)
- Nasal-swabs positive when collected early
- Nasal-sample results reflect air space concern

# Washington DC Processing & Distribution Center - “Brentwood”




**500,000 sq. feet**


**2421 employees**

**59 million pieces of  
incoming mail  
processed between  
10/12 and 10/21**

# How the Brentwood story begins...



# Spatial Association of Cases & Letter Route



Govt.  
Mails

High  
Speed  
Sorter

# Brentwood Postal Facility

## Temporal Association of Cases & Letters

Letters sorted at 7:10 AM

Sorter cleaned between 8 – 9:40 AM

Daschle Letter


Leahy Letter

Case 1

Case 2

Case 3


Case 4



October 12th

Lesson: Re-suspension risk unknown

# Surface Environmental Samples



Govt.  
Mails


High  
Speed  
Sorter

## Lessons

- Postal system – a complexity not anticipated
- Are we prepared for other scenarios: food, water?
- Surface sampling seemed to reflect risk area?




# Epidemic Curve for 22 Cases of Confirmed or Suspect Bioterrorism-Related Anthrax, United States, 2001



# Inhalational & Cutaneous Bioterrorism-Associated Anthrax Cases, United States, 2001

Characteristic	All Cases (n=22)	Inhalational Cases (n=11)	Cutaneous Cases (n=11)
Median Age in years (range)	46 (0.6 – 94)	56 (43 – 94)	35 (0.6 – 51)
Male Sex (%)	12 (55%)	7 (64%)	5 (45%)
Occupation			
Mail Handler	12 (55%)	8 (73%)	4 (36%)
Media Employee	6 (27%)	1 (9%)	5 (45%)
Other	4 (18%)	2 (18%)	2 (18%)
Mean incubation period in days	6.1	6.5	5.4
Number of deaths (case-fatality ratio)	5 (23%)	5 (45%)	0 (0%)

# Anthrax Disease Associated with Mail Paths & Intended Target Sites



# ***Bacillus anthracis* Activities Summary**

- **Clinical samples – 1000s**
- **Environmental samples – 100,000s**
- **Isolate confirmation and subtyping – 100s**
- **Phone calls from the public – 1000,000s**
- **Post-exposure Prophylaxis – app. 10,000**
  - **Must be followed closely!**
- **22 cases of anthrax, 5 deaths**

# Outline

- Investigation – Florida and Washington, D.C.
  - What were the gaps in our science base?
  - What were lessons at each step?
- **What were the challenges faced that might guide preparedness and research activities in anticipation of the next attack?**

# Challenges: Laboratory Diagnostic Methods Utility and Weaknesses


- Microscopy direct from clinical sample – useful (restrictions)
- Culture of *B. anthracis* – need alternatives for treated patient
- Immunohistochemical staining for *B. anthracis* antigens in tissue specimens – extremely useful, but further validation
- Serology for anti-*B. anthracis* antibodies by ELISA – validated during response, timeliness
- Polymerase chain reaction (PCR) for *B. anthracis* DNA in tissue specimens – useful (caveat = DNA prep.)

## Lessons

Assays must be evaluated and standardized now

- Other threat agents

# Challenges: Diagnosis in Treated Patient




# Challenges: Environmental Assessment

- Environmental assessment for BT event is tremendous
  - Not clearly planned
  - Not standardized or validated
  - Complicated by the many matrices
  - Sample management coordination strategies
  - Leadership is needed
- Sample transportation (and personnel too!)
  - Need for safe, reliable, efficient transport
- How can surface or air sampling after an attack be utilized to gauge risk? Standardized? Validated?



# Lab Environmental Response to Oct-Dec Anthrax Events



**DoD inclusive (25%)**  
**30,200 environmental tests performed**

**+ CDC inclusive (6%)**  
**7,500 environmental tests**

**PHL inclusive (69%)**  
**+ 84,010 environmental tests**


---

**Total:**  
**121,710 environmental tests**

**Laboratory Response Network for Bioterrorism, BPRP/NCID/CDC**



# Laboratory Response Network



# Challenges: Guidance on the efficacy of antibiotic prophylaxis for public health recommendations

- **Animal Studies**
  - Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. *J Hygiene* 54: 28-36.
  - Friedlander AM, Welkos SL, Pitt ML, et al. 1993. Postexposure prophylaxis against experimental inhalational anthrax. *JID* 167: 1239-42.
- **Questions**
  - Length of treatment with or without vaccine?
  - New antibiotics?
  - Adjunct therapies?

# Challenges: Post-exposure Prophylaxis Delivery National Pharmaceutical Stockpile



**Oct 8-January 11**

**143 sorties to 9 states**


**Delivered 3.75 million antibiotic tablets**

National to local a success

Local planning is critical

# Challenges: Post-exposure Prophylaxis Adherence

## Persons completing at least 60 days of PEP, by site



# Challenges: Anthrax Vaccine

**The anthrax vaccine used in the post-exposure program is considered investigational because:**

1. The vaccine is not approved for post-exposure prophylaxis;
2. The vaccine is not approved for a 3-dose regimen; and
3. The lot of vaccine to be used in this program is not approved for commercial use.

# Challenges: The Science of Re-suspension?

- Re-suspension was considered unlikely
- Re-suspension was detected in every indoor environment tested
- The degree and risk associated is poorly understood
  - product dependent
- Anticipate exposures to secondary aerosols
  - in laboratory and remediation and immunize now

# Consultation: “*Bacillus anthracis* Bioterrorism Research Priorities for Public Health Response”

- December 10-11, 2001, CDC, Atlanta, GA
- 132 Participants: CDC, FDA, NIH, EPA, DoD, DoE, USPD, DRES, State Health Depts., & Universities
- Working Grps: Powder Eval., Epidemiologic Investigation, Environ. assessment, Surveillance, Diagnosis, Treatment, PEP, & Remediation



# Summary Observations

- Unprecedented bioterrorism attack
- Letter transit paths associated with more morbidity & mortality than targets
- Clinical diagnosis is complicated by antibiotic treatment
- Environmental contamination and assessment presented unexpected challenges
- Disease clearly averted in some circumstances
- Preparedness worked: especially LRN and NPS
- Numerous knowledge gaps for public health response
- Clinical labs remain our front line, and we must focus support efforts for those individuals



*W.D. Hamilton*

*"And it was so typically brilliant of you to have invited an epidemiologist."*









